Celcuity Stock Soars 700% in a Year as One Investor's $17 Million Buy Helps Create Top Two Position

2026-02-22 14:25:11 ET

On February 17, 2026, Perceptive Advisors reported a buy of Celcuity (NASDAQ:CELC) , adding 203,881 shares in the fourth quarter, with an estimated transaction value of $16.76 million based on quarterly average pricing.

According to a Securities and Exchange Commission (SEC) filing dated February 17, 2026, Perceptive Advisors increased its stake in Celcuity by 203,881 shares in the fourth quarter. The estimated value of this share purchase, based on the period’s average closing price, is $16.76 million. The value of the fund’s position increased by $169.16 million over the quarter, a figure that reflects both the additional shares and price appreciation.

Celcuity is a clinical-stage biotechnology company specializing in the development of targeted cancer therapies and companion diagnostics. The company leverages its proprietary CELsignia platform and pipeline drug Gedatolisib to address unmet needs in oncology, particularly for breast and ovarian cancer. Its strategy centers on innovative diagnostic and therapeutic solutions, supported by a license agreement with Pfizer, positioning Celcuity to capitalize on advancements in precision medicine.

Continue reading